




MEDICAL TECHNOLOGY

Canè S.r.l. società unipersonale
P.IVA - Reg. Impr. TO: 04384410017
R.E.A. TO N. 629783
Cap. Soc. Euro 10.400 i.v.

SEP 13 2005

K052217

SINCERT



REG. N. 3506
UNI EN ISO 9001:2000
ISO 13485:2002

EXHIBIT 2

CANÈ S.r.l.
Via Pavia, 105/I 10090
Rivoli-Cascine Vica (Torino) Italy
Tel.: ++39-011-957.48.72
Fax ++39-011-959.88.80
Contact: Mario Canè, President
July 4, 2005

510(k) Summary

1. Identification of the Device:

Proprietary - Trade Name: Crono Super PID.

Classification Name: 80 FRN.

Common/Usual Name: Ambulatory Infusion Pump.

2. Equivalent legally marketed devices

This product is similar in function and design to the Crono cleared under 510(k) number K041414.

3. Indications for Use (intended use)

The portable Crono Super PID infusion devices have been designed for use in subcutaneous infusion of prescribed liquid medicines.

4. Description of the Device

Canè s.r.l., a company that specializes in the production of ambulatory pumps, has now produced a new generation of compact pumps: Crono, a perfect combination of high technology and innovative design.

Crono Super PID is an ambulatory syringe infusion pump intended for the controlled administration of liquids into the patients. This means that the pump can be worn during the infusion.

Crono Super PID combines high technology with innovative design. Thanks to the small size of the pump the patients can administer the drug any time during the day without interrupting daily life or leisure activities.

Crono Super PID pump uses dedicated syringes which are available in two sizes: 10 and 20 ml.

Crono Super PID has a particular mechanism which pushes directly on the rubber syringe piston, which makes it possible to reach a significant thrust force and high accuracy of administration.



MEDICAL TECHNOLOGY

Canè S.r.l. società unipersonale
P.IVA - Reg. Impr. TO: 04384410017
R.E.A. TO N. 629783
Cap. Soc. Euro 10.400 i.v.

SINCERT



REG. N. 3508
UNI EN ISO 9001:2000
ISO 13485:2002

Crono Super PID administers 22 µl per impulse.

In case of occlusion, an innovative infusion control system makes it possible to proceed with the infusion automatically and, after the occlusion is eliminated, to complete it.

Crono Super PID is fitted with a liquid cristal display which shows the time it takes to complete the delivery, the syringe size and the battery charge status.

5. Safety and Effectiveness, comparison to predicate device.

The results of bench, EMC, and user testing indicates that the new device is as safe and effective as the predicate device.

6. Substantial Equivalence Chart

| Characteristic | Crono - K041414 | Crono Super PID |
|---------------------------------|---|------------------------|
| Intended Use | Subcutaneous infusion of prescribed liquid medicines. | SAME |
| Physical characteristics | Crono - K041414 | Crono Super PID |
| Size | 3" x 1.85" x 1.14" (77 x 48 x 29 mm). | SAME |
| Weight | 4.0 oz (115 g) (battery included). | SAME |
| Battery | Power Source Lithium battery (3V) of the 123 A type. | SAME |
| Infusion per impulse | 22 µl. | SAME |
| Flow rate accuracy | +/-2%. | SAME |
| Max. Occlusion pressure | 4.5 bar +/-1 bar. | SAME |
| Capacity | 10 or 20 ml. | SAME |

7. Conclusion

After analyzing both bench and user testing data, it is the conclusion of CANÈ S.r.l. that Crono pumps are as safe and effective as the predicate device, has few software differences, and has no new indications for use, thus rendering it substantially equivalent to the predicate device.



SEP 13 2005

Food and Drug Administration
9200 Corporate Boulevard
Rockville MD 20850

Mr. Carlo Musso
Quality Manager
Cane S.R.L., Medical Technology
Via Pavia, 105/I 10090
Rivoli-Cascine Vica Torino
ITALY

Re: K052217

Trade/Device Name: Crono Super PID
Regulation Number: 21 CFR 880.5725
Regulation Name: Infusion pump
Regulatory Class: II
Product Code: FRN
Dated: July 26, 2005
Received: August 15, 2005

Dear Mr. Musso:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (240) 276-0115. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address <http://www.fda.gov/cdrh/industry/support/index.html>.

Sincerely yours,



Chiu Lin, Ph.D.

Director

Division of Anesthesiology, General Hospital

Infection Control and Dental Devices

Office of Device Evaluation

Center of Devices and

Radiological Health

Enclosure



MEDICAL TECHNOLOGY

Canè S.r.l. società unipersonale
P.IVA - Reg. Impr. TO: 04384410017
R.E.A. TO N. 629783
Cap. Soc. Euro 10.400 i.v.

SINCERT



REG. N. 3506
UNI EN ISO 9001:2000
ISO 13485:2002

j) Indications for Use

510(k) Number (if known): K052217

Device Name: Crono Super PID.

Indications For Use: the Crono Super PID has been designed for use in subcutaneous infusion of prescribed liquid medicines.

Prescription Use **X** .
(Part 21 CFR 801 Subpart D)

AND/OR

Over-The-Counter Use _____
(21 CFR 807 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Rud C. Chytra FOR ACW

(Division Sign-Off)
Division of Anesthesiology, General Hospital,
Infection Control, Dental Devices

510(k) Number: K052217